Takeda licenses 2 drugs to NPS for as much as $80M

03/20/2013 | Genetic Engineering & Biotechnology News

Takeda Pharmaceutical granted NPS Pharmaceuticals complete global rights to develop and market its adult short bowel syndrome drug teduglutide and recombinant human parathyroid hormone 1-84, which is approved in Europe for post-menopausal osteoporosis. The deal covers all assets related to the two products. NPS will pay Takeda $50 million in common stock and a potential $30 million milestone fee.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC